Perioperative Pembrolizumab Regimen Receives Positive CHMP Opinion in NSCLC
Pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab has been recommended for approval in high-risk NSCLC by the EMA's CHMP.
Source: onclive.com
Keynote 671 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Keynote 671. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Keynote 671 Today - Breaking & Trending Today
Evolving NSCLC Landscape: Comparing Recent Updates in Neoadjuvant and Perioperative Immunotherapy
An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.
Source: ajmc.com
ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types
The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.
Source: onclive.com
Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC
Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.
Source: onclive.com
Perioperative Pembrolizumab Shows Strong EFS, Response in Early-Stage NSCLC
The addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone resulted in a significant improvement in event-free survival and pathological response for patients with early-stage non–small cell lung cancer.
Source: onclive.com